iBio initiated with a Buy at JonesResearch

JonesResearch initiated coverage of iBio (IBIO) with a Buy rating and $7 price target The firm says the company’s extended half-life antibody platform is focused on obesity and metabolic indications. iBio’s is over 12 months away from clinical data, but the stock will move in sympathy with INHBE siRNA companies, the analyst tells investors in a research note.